Showing results (111-120 of 139) with videos related to

Sort By:
Pageof 14
Circulation|June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialSharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2012
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trialGlenn M Chertow, Ricardo Correa-Rotter, Geoffrey A Block, et al.
American Journal of Medical Genetics. Part A|January 8, 2005
Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort studySusan J Moore, Jane S Green, Yanli Fan, et al.
American Journal of Human Genetics|March 4, 2008
Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 geneNancy D Merner, Kathy A Hodgkinson, Annika F M Haywood, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 20, 2012
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo armHicham Skali, Julie Lin, Marc A Pfeffer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 25, 2023
Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysisMark J Sarnak, Rajiv Agarwal, Neil Boudville, et al.
The Journal of Clinical Endocrinology and Metabolism|October 11, 2013
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trialPatrick S Parfrey, Glenn M Chertow, Geoffrey A Block, et al.
The New England Journal of Medicine|November 6, 2012
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis, Glenn M Chertow, Geoffrey A Block, et al.
Hemodialysis International. International Symposium on Home Hemodialysis|November 14, 2015
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trialPatrick H Pun, Safa Abdalla, Geoffrey A Block, et al.
Journal of the American Heart Association|November 19, 2014
Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trialDavid C Wheeler, Gerard M London, Patrick S Parfrey, et al.
Pageof 14